Which exemption allows for the usage of standard packaging for specific medications under PPPA?

The exemption that allows for the usage of standard packaging for specific medications under the Poison Prevention Packaging Act (PPPA) is indeed related to isosorbide dinitrate sublingual or chewable tablets of 10 mg or less. This medication is specifically listed due to its low risk of toxicity and the fact that it is typically prescribed for acute angina attacks, requiring patients to have quicker access to the medication without the barrier of child-resistant packaging.

When medications fall under the exemptions established by the PPPA, they do not require the stringent child-resistant packaging that is ordinarily mandated for most pharmaceuticals. In the case of isosorbide dinitrate, the exemption recognizes that this formulation is often used in situations where immediate access is essential, and the risk of poisoning in children is considered minimal given the usual circumstances of use.

The other options do not have similarly specific exemptions. For instance, all tablet forms of medications and prescription pain relief medications generally require child-resistant packaging due to their larger risk profiles. While cough syrup for children may have some exceptions regarding packaging for specific formulations, it does not fall into the same category as the specific exemption seen with isosorbide dinitrate.